Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
Stocks · News reference
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call
Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you
8-K filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Filed: 2026-10-05 AccNo: 0001104659-26-113763 Size: 21 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits